JAMA Oncology Author Interviews

Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in ERBB2-Positive Breast Cancer

Jun 24, 2021

13:01

forum

Ask episode

view_agenda

Chapters

auto_awesome

Transcript

info_circle

Episode notes

Interview with Thomas Hatschek, MD, PhD, author of Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial

Home Top podcasts Popular guests Top books